assignment
Recruiting

Randomized, Double-Blind, Event-Driven Trial of Posaconazole vs. Fluconazole for Antifungal Prophylaxis in Acute Myeloid Leukemia Patients

Trial ID
2024-517211-79-00
Protocol
PTX3-AML

Register record, history and transparency: CTIS.eu

Trial statistics

science
9
test molecules
location_city
3
research sites
public
2
countries
medical_information
1
disease
person_search
4
investigators

Diseases & Conditions

Fungal infection

Objectives

The primary objective of this clinical trial is to demonstrate that, in the high-risk strata, the probability of experiencing proven and probable **invasive mold infections** (IMI) during the treatment period (days 0-180) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) treated with posaconazole is lower than in those treated with fluconazole. This is clinically relevant as it aims to establish the superiority of posaconazole in reducing the risk of IMI, which is a significant complication in immunocompromised patients.

Secondary objectives include:

  • To determine whether in the low-risk strata, the probability of experiencing proven and probable IMI during the treatment period in patients treated with posaconazole is lower than in those treated with fluconazole, with an absolute risk reduction (ARR) greater than 0.
  • To compare the ARR obtained by the use of posaconazole versus fluconazole prophylaxis on the cumulative incidence of proven and probable IMI in AML/MDS patients between high-risk and low-risk strata, and accordingly compare the number of patients needed-to-treat (NNT) between these strata.
  • To identify whether the risk reduction of experiencing proven and probable IMI between posaconazole versus fluconazole prophylaxis differs between genetically risk-stratified groups, specifically if the hazard ratio is dependent on PTX3 single nucleotide polymorphisms (SNPs).
  • To evaluate the above objectives (primary and secondary) on secondary outcomes.

Participants

The clinical trial involves a total of **167 participants** diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDSit), who are undergoing an intensive chemotherapy regimen. The study population includes both **male and female** subjects aged 18 years and older. Participants were selected based on their diagnosis and treatment plan, which includes induction, consolidation, or salvage chemotherapy, and a planned hospital admission during the neutropenic phase. The trial does not involve a vulnerable population. Lifestyle factors such as diet and physical activity are not specified as part of the selection criteria. The primary focus is on evaluating antifungal prophylaxis in this patient group, with the aim of reducing the risk of invasive mold infections during the treatment period.

Plans and Procedures

The clinical trial is designed as a **randomized**, **double-blind**, controlled study aimed at evaluating the efficacy of antifungal prophylaxis in patients with **acute myeloid leukemia** (AML). The trial will compare the effectiveness of **posaconazole** against **fluconazole** in reducing the incidence of invasive mold infections over a treatment period of 180 days. The study is event-driven and genetically stratified, ensuring that participants are allocated to treatment groups based on genetic risk factors. The trial is expected to conclude by November 30, 2025, with recruitment having commenced on March 3, 2020.

Participants will undergo a series of study visits, beginning with an inclusion visit where eligibility is confirmed through criteria such as age (≥18 years), diagnosis of AML or MDSit, and planned hospital admission during the neutropenic phase. Following the inclusion visit, participants will be randomized to receive either posaconazole or fluconazole. The study includes regular follow-up visits to monitor the incidence of proven and probable invasive fungal infections, as well as to assess safety through the evaluation of adverse events, including liver test elevations and QTc interval prolongation on ECG. The end-of-study visit will occur at the 180-day mark, where the primary endpoint, the cumulative incidence of invasive fungal infections, will be assessed.

Participant involvement is expected to last for the full 180-day treatment period unless early termination is warranted. Conditions that may lead to early termination include the occurrence of severe adverse events or withdrawal of consent. The trial's primary endpoint is the cumulative incidence of proven and probable invasive fungal infections by day 180. Secondary endpoints include the incidence of possible infections, overall survival, and the frequency of adverse events. The trial is conducted under strict regulatory compliance, ensuring the safety and well-being of all participants throughout the study duration.

Treatment

The clinical trial involves the administration of several **experimental medications** for antifungal prophylaxis in patients with acute myeloid leukemia. The first medication is **Diflucan 50 mg Hartkapseln**, which contains the active substance **fluconazole**. This medication is provided in the form of a hard capsule and is administered orally. The maximum daily dose is 400 mg, with a total maximum dose of 72,000 mg over a treatment period of up to 180 days. The administration route is oral, and participant compliance is monitored throughout the trial.

Another experimental medication used in the trial is **POSACONAZOLE VIATRIS 40 mg/mL, suspension buvable**, containing the active substance **posaconazole**. This medication is formulated as an oral suspension and is also administered orally. The maximum daily dose is 300 mg, with a total maximum dose of 54,000 mg over the same treatment period of 180 days. The oral route of administration is maintained, and adherence to the dosing schedule is closely monitored.

**FLUCONAZOLE ARROW 50 mg, gélule** is another formulation of **fluconazole** used in the trial. It is provided as a hard capsule for oral use, with a maximum daily dose of 400 mg and a total maximum dose of 72,000 mg over 180 days. The administration is oral, and compliance is tracked to ensure adherence to the treatment regimen.

The trial also includes **POSACONAZOLE ZENTIVA 100 mg, comprimé gastro-résistant**, which contains **posaconazole**. This medication is available as a gastro-resistant tablet and is administered orally. The dosing schedule allows for a maximum daily dose of 300 mg and a total maximum dose of 54,000 mg over the treatment period. Oral administration is maintained, and participant compliance is monitored.

**FLUCONAZOLE ARROW 200 mg, gélule** is another **fluconazole** formulation used in the study. It is provided as a hard capsule for oral administration, with a maximum daily dose of 400 mg and a total maximum dose of 72,000 mg over 180 days. The oral route is used, and adherence to the dosing schedule is monitored.

**Diflucan 2 mg/ml Infusionslösung** is a solution for infusion containing **fluconazole**. This formulation is administered intravenously, with a maximum daily dose of 400 mg and a total maximum dose of 72,000 mg over the treatment period. Intravenous administration is used, and compliance is monitored to ensure proper dosing.

**Noxafil 40 mg/mL oral suspension** is another formulation of **posaconazole** used in the trial. It is provided as an oral suspension and administered orally. The maximum daily dose is 300 mg, with a total maximum dose of 54,000 mg over 180 days. Oral administration is maintained, and participant compliance is tracked.

Lastly, **FLUCONAZOLE KABI 2 mg/ml, solution pour perfusion** is a solution for infusion containing **fluconazole**. This medication is administered intravenously, with a maximum daily dose of 400 mg and a total maximum dose of 72,000 mg over the treatment period. Intravenous administration is used, and adherence to the dosing schedule is monitored.

Efficacy

Efficacy in this clinical trial will be assessed by evaluating the incidence of invasive mold infections in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) treated with either **posaconazole** or **fluconazole**. The primary endpoint is the cumulative incidence of proven and probable invasive fungal infections, including invasive mold infections and invasive aspergillosis, at 180 days. This is defined as the proportion of patients who experience these infections within 180 days from the first dose of antifungal prophylaxis treatment after randomization.

Secondary endpoints include the cumulative incidence of possible invasive mold infections by day 180 in the intention-to-treat (ITT) population, the time to probable and proven invasive mold infections during 180 days, and overall survival in the ITT population by day 180. Additionally, the trial will assess the time to first use and the number of patient-days of amphotericin B or an echinocandin, as well as the frequency and distribution of adverse events of interest, such as elevation of liver tests and prolongation of the QTc interval on ECG, in participants treated with posaconazole and fluconazole. The cumulative incidence of probable and proven invasive fungal infections in the per protocol (PP) population by day 180 will also be evaluated.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Signed informed consent according to national/local regulations
  • Age ≥18 years
  • Diagnosis of AML or MDSit (de novo or secondary) treated with an intensive chemotherapy regimen, including induction / consolidation / salvage chemotherapy
  • Planned hospital admission for the duration of the neutropenic phase (ANC<500 cells/mm3)
cancel

Exclusion Criteria

  • Patients with neutropenia (ANC<500 cells/mm3) at hospital admission (first inpatient blood analysis)
  • Patients with a diagnosis of acute promyelocytic leukemia (APL) or AML-M3
  • Patients with known history of allergy, hypersensitivity or serious reaction to azole antifungals
  • Women who are pregnant (positive blood/urine pregnancy test within 10 days before randomization) or breast feeding
  • Diagnosis and treatment for an IFI within 3 months prior to study enrolment and an IMI at any point prior to or at the time of enrolment
  • Severe liver dysfunction, defined as at least one of the following markers: AST, ALT, alkaline phosphatase, and/or total bilirubin above >5x upper limit of normality documented on the first inpatient analysis if still present at inclusion and considered contra-indicated by the clinical team
  • Patients with a prolonged QTc interval on at least 2 electrocardiograms (ECG): QTc greater than 450 msec for men and greater than 470 msec for women, and if considered contra-indicated by the clinical team
  • Patients who are receiving and cannot discontinue the following drugs at least 24 hours prior to randomization: terfenadine, astemizole, cisapride, pimozide, halofantrine or quinidine (because of the possibility of QT prolongation), sirolimus, rifampin, rifabutin, carbamazepine, long acting barbiturates (e.g., phenobarbital, mephobarbital), ritonavir, efavirenz, or ergot alkaloids (e.g., ergotamine, dihydroergotamine)
  • Serious uncontrolled concomitant disease or comorbidity that, in the opinion of the investigator, may compromise adherence to the study protocol
  • Receipt of a prior allogeneic HCT
  • Previous exposure to mold-active prophylaxis (>48 hours within 7 days of inclusion).
  • Patients with relapsed leukemia already included in the trial

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Belgium BelgiumRecruiting03 Mar 202062
France FranceRecruiting03 Mar 202040

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
Diflucan 2 mg/ml Infusionslösung
TestINFUSIONSLÖSUNGINTRAVENOUS USE400180PRD1759007
FLUCONAZOLE KABI 2 mg/ml, solution pour perfusion.
TestSOLUTION POUR PERFUSIONINTRAVENOUS USE400180PRD1163394
FLUCONAZOLE ARROW 200 mg, gélule
TestGÉLULEORAL USE400180PRD1747231
Noxafil 40 mg/mL oral suspension
TestORAL SUSPENSIONORAL USE300180PRD2825288
FLUCONAZOLE ARROW 50 mg, gélule
TestGÉLULEORAL USE400180PRD1747229
POSACONAZOLE ZENTIVA 100 mg, comprimé gastro-résistant
TestCOMPRIMÉ GASTRO-RÉSISTANTORAL USE300180PRD7663441
POSACONAZOLE VIATRIS 40 mg/mL, suspension buvable
TestSUSPENSION BUVABLEORAL USE300180PRD10079753
Diflucan 50 mg Hartkapseln
TestHARTKAPSELNORAL USE400180PRD1759071
Noxafil 40 mg/mL oral suspension
TestORAL SUSPENSIONORAL USE300180PRD2945137

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Fluconazole
11 trials

Also investigated for

Fungal infection 4Systemic candida 3Bacterial infection 1Laryngeal leukoplakia 1
vaccines
Posaconazole
11 trials

Also investigated for

Acute myeloid leukaemia 4Fungal infection 4Myelodysplastic syndrome 2Acute graft versus host disease 1